US EditionPublished • loading... • Updated
Biocon gets notice of compliance from Health Canada for two biosimilars
Summary by NewsDrum
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Biocon gets notice of compliance from Health Canada for two biosimilars
New Delhi, Apr 21 (PTI) Biocon Ltd on Tuesday said it has received a notice of compliance from Health Canada for its biosimilars Bosaya and Vevzuo, indicated for the treatment of osteoporosis and bone complications associated with cancer. Health Canada has granted a notice of compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vevzuo (denosumab), a biosimilar to Xgeva, on April 3, 2026, Biocon Ltd said in a regulatory filing. "B…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
